So far in 2018, AstraZeneca (AZN) has seen strong performance from its new medicines coupled with a surge in emerging market sales. Additionally, the company expects improved performance from product sales in the second half and critical news flow from its research pipeline. The company saw strong sales gains in China.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,